Diagnostic accuracy of central vein sign on MRI in pediatric-onset multiple sclerosis: A systematic review and meta-analysis.

Clin ImagingJul 25, 2026 (epub)
Clinical ResearchNeurologyPediatrics

Omar Al Dabssi, Muataz Kashbour, Ruaa Mustafa Qafesha et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the diagnostic accuracy of the Central Vein Sign (CVS) in pediatric-onset multiple sclerosis (POMS). Analyzing five studies with 128 patients, the pooled proportion of CVS-positive patients was 0.643, indicating potential diagnostic value for CVS in POMS, though pediatric-specific criteria are necessary.

Key findings

  • The pooled proportion of CVS-positive patients was 0.643 (95% CI: 0.253 to 1.032, p < 0.001).
  • The pooled number of CVS-positive lesions was 13.851 (95% CI: 11.260 to 16.442, p = 0.829).
  • The mean CVS-positive rate ratio was 0.531 (95% CI: 0.346 to 0.715, p < 0.001).
  • The highest CVS lesion burden was found in periventricular regions (mean = 4.62, 95% CI: 3.39-5.85, p = 0.249).

Why it matters

Understanding the diagnostic accuracy of the Central Vein Sign in pediatric-onset multiple sclerosis can aid clinicians in differentiating POMS from other demyelinating disorders, potentially leading to more accurate diagnoses and timely interventions.

Source

PubMed · PMID 42520617

Published in Clin Imaging. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.